Personalized medicine and immunotherapy are changing the landscape of cancer diagnosis and treatment. Traditionally, the one-biomarker-per-drug model has been driving the development of single companion diagnostic tests to inform patient selection for drug therapy. This simple paradigm has been questioned recently, as our understanding of the complexity of tumor development has advanced—a single biomarker may provide insufficient information for accurate patient stratification. Importantly, the development of multiple tests for the same biomarker, often for the same indication, has further complicated the analysis. A classic example is the case of PD-L1, for which there are currently five different immunohistochemistry assays for use with five different PD-1/PD-L1 monoclonal antibody therapies.

In this webinar, using PD-L1 as a case study, our expert panel will discuss:

• The current landscape and challenges of using single-protein biomarkers
• The complexities inherent in using a different assay for each anti-PD-1/PD-L1 drug
• Potential solutions to this problem, such as the move toward multibiomarker panels.

If you’ve already registered, please click here to login to the webinar.